Key Drivers
- Gross Margin
- Operating Losses
- Rising Leverage
AIAI Summary
SNDX has shifted from a speculative pipeline story to an emerging commercial oncology business with real revenue traction from Revuforj and Niktimvo, but the investment now hinges on whether management can translate that growth into operating leverage before ongoing losses and the new convertible financing lead to dilution or cap upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Operating Losses
- •Rising Leverage
SNDX combines strong product gross margins and adequate liquidity with persistent operating losses, negative free cash flow, rising leverage, and a still-expensive valuation, keeping financial risk high. ക ക
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •$20.00 reclaim
- •Resistance stall
Over the last month, SNDX rebounded from a $16.96 low to $21.82, reclaimed $20.00, and is now stalling at $21.80-$21.90 resistance, leaving $20.89 as the key near-term hold.
Sharp rebound from $16.96 low to $21.82 after a short-term downtrend
Sentiment & News
Key News Insights:
- •Revuforj momentum
- •AML expansion
- •Commercial scaling
Syndax's recent updates underscore accelerating commercial momentum from Revuforj and Niktimvo, reinforced by strong AML clinical data, investor outreach, and continued hiring as it scales.
The news is modestly positive for the stock as it supports growth visibility, clinical differentiation, and execution confidence
Similar Companies in Healthcare
Other companies in the same sector with AI ratings